A Phase 1, Multicenter, Open-label, Dose Escalation/expansion Study Evaluating the Safety, Pharmacokinetics and Preliminary Efficacy of CX1003 (Kanitinib) in the Patients with Relapsed Advanced or Metastatic Solid Tumors
Overview
- Phase
- Phase 1
- Intervention
- CX1003
- Conditions
- Advanced Solid Tumor
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
- Enrollment
- 126
- Locations
- 1
- Primary Endpoint
- Maximum tolerated dose (MTD): Dose Escalation Stage
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
CX1003 is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit vascular endothelial growth factor receptor 2 (VEGFR2) and hepatocyte growth factor receptor (HGFR/MET). This study aimed to evaluate the safety, pharmacokinetics, and antitumor activity of CX1003 in patients with refractory advanced or metastatic solid tumors.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologically or cytologically confirmed recurrent or metastatic solid tumors;
- •At least one measurable lesion (spiral CT scan long diameter ≥10 mm or enlarged lymph node short diameter ≥15 mm by RECIST 1.1);
- •Documented disease progression after, or refractory to, or intolerant of prior standard or established therapy known to provide clinical benefit for their condition; or documented disease progression within 24 weeks after prior adjuvant/neoadjuvant therapy;
- •ECOG PS ≤1;
- •Expected overall survival≥12 weeks;
Exclusion Criteria
- •Untreated brain metastases or symptoms of brain metastases cannot be controlled more than 4 weeks;
- •Other kinds of malignancies \[excluding stage IB or lower grade cervical cancer，noninvasive basal cell or squamous cell cancer, breast cancer with complete remission (CR) \> 10 years ,melanoma with CR \> 10 years or other malignant tumors with CR \> 5 years\];
- •Hematologic, renal, and hepatic function abnormities as defined below:
- •Absolute neutrophil count (ANC) \<1.5×109 /L or platelet \<100×109 /L or hemoglobin \<9 g/dL; Total bilirubin \> 1.5×the upper limit of normal range(ULN) without liver metastases; total bilirubin \> 3×ULN with liver metastases; AST, ALT, ALP \>1.5×ULN without liver metastases ; AST, ALT, ALP \>5×ULN with liver metastases; Primary hepatocellular carcinoma; Hepatic cirrhosis with Child-Pugh B or C; Serum creatinine \>1.5×ULN; History of previous nephrotic syndrome; INR or aPPT \>1.5×ULN; Presence of hemorrhage (hemoptysis) , thrombosis，or currently receiving treatment with warfarin, aspirin, low molecular weight heparin (LMWH), or any other anti-platelet drugs (Aspirin ≤100 mg/d for prophylaxis are allowed); •Any of the following gastrointestinal disease: Unable to swallow oral drugs; Need intravenous nutrition; History of a gastric resection; History of treatment for active peptic ulcer disease within 6 months; Clinically significant gastrointestinal bleeding within 3 months; Persistent grade 2 or higher chronic diarrhea despite optimal medical management;
- •Any of the following cardiovascular and cerebrovascular disease: Myocardial infarction , severe cardiac arrhythmias, unstable angina, coronary artery disease, congestive heart failure, cerebrovascular accident or TIA within 12 months ; Deep vein thrombosis or pulmonary embolism within 6 months; QTcF \>470 msec; Uncontrolled hypertension despite optimal medical management;
- •Presence of unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5.0 grade 0 or 1 with the exception of alopecia;
- •Involved in other clinical trials within 30 days of enrollment;
- •Major surgical procedure, open biopsy, or significant traumatic injury within 30 days of enrollment;
- •History of organ allograft ;
- •Need glucocorticoids or other immunosuppressive agents for immunosuppression (excluding local or inhaled glucocorticoids);
Arms & Interventions
Treatment (CX1003)
Treatment will comprise 2 periods: a 4-day single dose period, followed by a period of daily-dose in continuous 28-day treatment cycle (the 1st cycle) or 21-day treatment cycles (the 2nd cycle and beyond).
Intervention: CX1003
Outcomes
Primary Outcomes
Maximum tolerated dose (MTD): Dose Escalation Stage
Time Frame: First 5 weeks after initial administration of CX1003
The maximum tolerated dose (MTD) was defined as the highest dose for a given schedule that was expected to cause DLTs in no more than 33% of patients.
Incidence of dose-limiting toxicities (DLTs) by NCI CTCAE 5.0: Dose Escalation Stage
Time Frame: First 5 weeks after initial administration of CX1003
Occurrence of any of the following toxicities was considered DLT if judged by the Investigator to be possibly, probably, or definitely related to the administration of CX1003: * Any Grade 3 or higher non-hematologic toxicity (including persisting nausea, vomiting, diarrhea, and electrolyte imbalances despite optimal medical management); * Grade 4 neutropenia for \>5 consecutive days; * Grade 3 or higher febrile neutropenia; * Grade 3 or higher neutropenia associated with infection; * Grade 4 thrombocytopenia; * Grade 3 or higher thrombocytopenia with clinically significant bleeding or that requires a platelet transfusion.
Secondary Outcomes
- Pharmacokinetics (PK) profile: CL/F(First 5 weeks after initial administration of CX1003)
- Progression-free survival (PFS)(up to 24 months)
- Disease Control Rate (DCR)(up to 24 months)
- Pharmacokinetics (PK) profile: Cmax(First 5 weeks after initial administration of CX1003)
- Pharmacokinetics (PK) profile: Tmax(First 5 weeks after initial administration of CX1003)
- Objective Response Rate (ORR)(up to 24 months)
- Pharmacokinetics (PK) profile: T1/2(First 5 weeks after initial administration of CX1003)
- Pharmacokinetics (PK) profile: AUC(First 5 weeks after initial administration of CX1003)
- Pharmacokinetics (PK) profile: Vz/F(First 5 weeks after initial administration of CX1003)
- Duration of Response (DOR)(up to 24 months)
- Safety profile as assessed by the incidence, duration, and severity of adverse events(From first dose of CX1003 to 30 days after last dose)